Fake goods may undo China-Africa trade

Trade between China and Africa has been one of the dominant issues on the table this decade. Many high-level meetings have been conducted seeking to liberalize movement of goods in these regions. The talks formed part of the wider plan for the realization of South-South trade. But underneath this "barrierless" trade regime lurks some danger: fake goods. The majority of counterfeited products entering Africa are drugs. According to the World Health Organization, around 10 percent of drug supplies in developing countries are counterfeit medicines. These have caused thousands of deaths annually.

New report signals slowdown in the fight against malaria

According to the World Malaria report 2012, 50 countries around the world are on track to reduce their malaria case incidence rates by 75% by 2015 – in line with World Health Assembly and Roll Back Malaria targets. However, these 50 countries only represent 3%, or 7 million, of the malaria cases that were estimated to have occurred in 2000, the benchmark against which progress is measured.

New report offers insights into the threats posed by falsified medicines and highlights need for better coordinated global approaches to protect public health

Geneva, 11 December 2012 - A study released today highlights opportunities for a better coordinated international response to the threat of falsified, or counterfeit, medicines. The prevention of pharmaceutical falsification should be seen as an integral part of the global health community’s effort to improve access to effective, good quality medicines and protect public health worldwide.

G-FINDER survey highlights increased industry investment in R&D for neglected diseases

The recently released fifth G-FINDER survey reports on 2011 global investment into research and development of new products for neglected diseases, and identifies trends and patterns across the five years of global G-FINDER data. In 2011, reported funding for neglected disease R&D was $3.05 billion. Both public and philanthropic funding have dropped away since the global financial crisis, but industry funding has increased dramatically over the survey period, predominantly due to increased investments from multinational pharmaceutical companies (MNCs).

Report finds Big Pharma is doing more for access to medicine in developing countries than two years ago

The latest Access to Medicine Index, which ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in developing countries, finds that the industry is doing more than it was two years ago, with GlaxoSmithKline still outperforming its peers, but an expanding group of leaders closing the gap. Companies are developing more products for more diseases that particularly affect the world’s poor, and collaborating more in the process than they were two years ago. In addition, more companies are using tiered pricing schemes to lower prices for certain countries or population groups within a country, and applying them to a broader range of products and in more countries.

Global partners in fighting disease

Twenty-five years ago last month, something big started, a collaborative venture that changed the lives of hundreds of millions of people. In October 1987, Roy Vagelos, then the chief executive of Merck, launched the largest pharmaco-philanthropic venture ever. He approached me, as the head of the Task Force for Child Survival in Atlanta, and offered the drug — now copyrighted as Mectizan — for free if the task force could devise a distribution system.
The original target of treating 6 million people in six years was achieved in four years. Only 15 years after the program started, 250 million treatments had been given. Last year, the Mectizan Donation Program provided 140 million treatments for onchocerciasis in Africa, Latin America and Yemen. A ­quarter-century after the program began, 1 billion treatments have been provided free by ­Merck.

USD 3 Million Awarded to Find Biomarkers for Potential Test of Cure for Chagas Disease

Wellcome Trust to fund three-year study in Texas to look for new biological markers measuring treatment efficacy for the leading parasitic killer of the Americas. Chagas disease infects approximately 8 million people worldwide and is the leading parasitic killer in the Americas, where it causes more deaths than malaria.

Open Access Initiative Reveals Drug Hits for Deadly Neglected Tropical Diseases

The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announce today the identification of three chemical series targeting the treatment of deadly neglected tropical diseases (NTDs), through DNDi's screening of MMV's open access Malaria Box. The resulting DNDi screening data are among the first data generated on the Malaria Box to be released into the public domain, exemplifying the potential of openly sharing drug development data for neglected patients.

Rotary International and Global Partners Contribute to a Polio-Free India

Washington, D.C. (November 3, 2012) —The Pharmaceutical Research and Manufacturers of America (PhRMA) and its members are pleased to celebrate one of the most significant global health achievements of the 21st century. For over the past three years, we have supported Rotary International’s PolioPlus program in India through grants and contributions, some of which have been matched by the Bill and Melinda Gates Foundation.

Policies that encourage innovation in middle-income countries: IFPMA report

An independent study on biopharmaceutical innovation in middle-income countries was released today at the 26th IFPMA Assembly in Geneva. The report analyzed key national political and economic factors that foster biopharmaceutical innovation. The report highlighted the primary success factor as consistent long-term policy and legal frameworks. These should be coupled with effective coordination of national industrial and health policies, encouragement of collaborations between stakeholders, and adequate intellectual property protection. The report further suggests that some countries specialize in those stages of the innovation process in which they have a competitive advantage.